


# LTL-283 datasheet


<b>Origin</b>	Primary human skin cancer	<b>Histopathology</b>	Skin melanoma
<b>Year of establishment</b>	2007	<b>Doubling time</b>	5 days (sub-renal)
<b>Local invasion</b>	Yes	<b>Metastasis</b>	No
<b>Drug sensitivity</b>	Not determined		

The LTL-283 was developed from a patient's primary human melanoma. Histopathologically, it closely resembles the patient's tumor (Figs 1, 2). When grafted under the renal capsules of SCID mice, the LTL-283 shows local invasion into adjacent host kidney parenchyma. No metastasis was observed.



**Fig. 1. H&E stained LTL-283 tissue sections.**

The LTL-283 is composed of diffused melanoma cells with large nuclei and prominent eosinophilic nucleoli, closely resembling the pathological characteristics of the original patient's cancer (Fig. 2) (x400)



**Fig. 2. Patient's cancer tissue before grafting.**

Showing a malignant melanoma from skin. The tumor cells grow in a diffuse pattern, and contain prominent eosinophilic nucleoli. (400x)

## **Genetic and epigenetic characteristics**

Tissue microarrays containing LTL-283 tissue are available for screening potential molecular targets.

## **Applications**

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, and angiogenesis.
2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.
3. Study of mechanisms underlying tumor growth and progression.

**For more information, please contact us by email: [LTL@brrcr.ca](mailto:LTL@brrcr.ca) or phone: (604) 675 8013**